BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, announced that Jack Crowley has joined the company as Chief Financial Officer. Mr. Crowley is a seasoned executive with extensive experience overseeing finance organizations for Fortune 500 and private equity-backed companies. He most recently served as CFO at Lantheus Medical Imaging Inc., where he led the team through a successful transition from a private equity-backed to a publicly-traded global life sciences company.
“We are thrilled to have Jack join PGDx as we continue to build the management team and prepare for our next phase of growth,” said Doug Ward, Chief Executive Officer. “Jack brings proven leadership in growing healthcare companies and has been instrumental in providing the financial vision and strategy to take organizations to the next level. His experience will be invaluable as we continue to execute on our strategic and operating plans and our commitment to delivering a portfolio of regulated tissue and liquid biopsy genomic products to laboratories worldwide.”
Mr. Crowley brings more than 25 years of finance and operations experience to PGDx, previously serving as Chief Financial Officer and Treasurer at Lantheus with responsibility for all finance, information technology, and investor relationship activities. He led transformational recapitalization efforts following Lantheus’ IPO in 2015, and his prior roles at the company included Chief Accounting Offer, Vice President of Finance, and Global Corporate Controller. Before joining Lantheus, Mr. Crowley served as Director of Finance and Assistant Corporate Controller of Biogen Idec, the Director of Accounting at Thermo Fischer Scientific, and a Senior Manager in the Audit practice of PricewaterhouseCoopers LLP. Mr. Crowley, who is a Certified Public Accountant, holds a Master of Business Administration from the University of Massachusetts and a Bachelor of Science in Business Administration from Westfield State University.
About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. For additional information, visit www.PersonalGenome.com.
Business Wire source: